 - Consenting participants who qualify during the screening process, will undergo apheresis. Randomization, through a web-based system will take place immediately after successful apheresis. The cell collection samples will be sent to a cell manufacturing facility for manufacturing according to the treatment allocation of: aPlacebo Plasma-Lyte A 25 autologous plasma, bEPCs or cEPCs transfected with human endothelial nitric oxide synthase eNOS. 